Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive.
NEW YORK, Aug. 1, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/oasm.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Oasmia engaged in improper related-party transactions with Alceco International S.A. and Ardenia Investment LTD, which were controlled by Defendant Aleksov and his former father-in-law; (2) due to those transactions, millions of Swedish kronor were not accounted for in Oasmia’s books; (3) transactions concerning Oasmia’s patents were also “carried out in a doubtful way;" and (4) as a result of the aforementioned misconduct, defendants’ statements about Oasmia’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/oasm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Oasmia you have until September 27, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert---oasmia-pharmaceutical-ab-oasm---bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-and-lead-plaintiff-deadline-september-27-2019-300892986.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Company Codes: NASDAQ-SMALL:OASM
